Cargando…
Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
Cancer immunotherapies targeting immune checkpoint pathways, such as programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), have achieved unprecedented therapeutic success in treating various types of cancer. The prominent and...
Autores principales: | Lee, Junghwa, Kim, Eui Ho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443702/ https://www.ncbi.nlm.nih.gov/pubmed/37614504 http://dx.doi.org/10.3389/fonc.2023.1233376 |
Ejemplares similares
-
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
por: Boyero, Laura, et al.
Publicado: (2020) -
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
por: Swart, Maarten, et al.
Publicado: (2016) -
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
por: Russell, Bonnie L., et al.
Publicado: (2021) -
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
por: Kok, Victor C.
Publicado: (2020) -
Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
por: Scott, Susan C., et al.
Publicado: (2022)